What C17 Council does

C17 Council (legal name: C17 Council - Children's Cancer & Blood Disorders) is a Canadian non-profit organization founded in 2005 that serves as the national coordinating body for pediatric hematology, oncology, and stem cell transplant programs across Canada. It represents the institutionally appointed heads of all 16 academic pediatric oncology/hematology programs at 17 Canadian centres, and functions as the authoritative national voice for children and adolescents with cancer and serious blood disorders. C17 operates through a Council governance structure supported by nine standing committees covering Research Network, Senior Medical Office (COG regulatory affairs), Education, Human Resources, CYP-C/CCJC surveillance, Adolescents & Young Adults with Cancer, and Developmental Therapeutics.

C17's product surface spans the C17 Research Network (which administers an annual peer-reviewed national grant competition), the CYP-C national pediatric cancer surveillance program operated jointly with PHAC and CPAC, the U-Link.care early-phase clinical trial portal, the 100% Fund for hard-to-treat pediatric cancers, the DVL Committee network of 11 Phase I/II trial centres, and a structured Research Champion webinar training series. Technical assets are primarily coordination and data infrastructure: REDCap-based research application forms, a member portal for protocol submissions and grant management, and aggregate-data dashboards. C17 holds the official Canadian Senior Medical Officer appointment for the Children's Oncology Group (COG) and operates a long-standing joint early-phase trial collaboration with the Canadian Cancer Trials Group (CCTG) dating to September 2010.

C17 does not generate commercial revenue. It is funded through a coalition of national foundations (Childhood Cancer Canada, Kids With Cancer Society, Hyundai Hope on Wheels Canada, Hospital for Sick Children Foundation, the 100% Fund family foundations), government partners (PHAC, CPAC), and corporate sponsors. Cumulative research grant administration exceeds $6.5M CAD since 2005, and a 2026 Hyundai Hope on Wheels Canada partnership added approximately $1.04M CAD in new funding. The organization is headquartered in Edmonton, Alberta, employs roughly 11 named staff and coordinators, and is led by Executive Director Kathy Brodeur-Robb.

Name

C17 Council

Legal name

C17 Council - Children's Cancer & Blood Disorders

Website

https://c17.ca

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

C17 Council is the Canadian national non-profit council representing all 16 academic pediatric hematology, oncology, and stem cell transplant programs across 17 centres, coordinating research grants, clinical trial access, surveillance data, and education for children with cancer and blood disorders in Canada.

Ownership category

akta.pro rank

Product category

Pediatric Oncology Research Coordination

NAICS

Professional Organizations (813920)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Clinical Research Support (CRC/CTA) (EDAOAJAO)

akta.pro secondary industry

Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)

Keywords

• Pediatric oncology research
• Clinical trial coordination
• Research grant administration
• Cancer surveillance data
• Healthcare research network

Headquarters

HQ city

Edmonton

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Research Grant Funding: C17 does not generate commercial revenue. It functions as a non-profit research coordination body funded through foundation grants, government partnerships, and corporate sponsorships. Funding partners (e.g., Childhood Cancer Canada, Kids With Cancer Society, Hyundai Hope on Wheels Canada) provide grants that C17 administers through its Research Network competition to Canadian investigators.
2. Partnership & Sponsorship Revenue: C17 receives programmatic funding and grants from national foundations and corporate sponsors (e.g., Hyundai Hope on Wheels Canada, Hospital for Sick Children Foundation) in exchange for partnership recognition, grant co-administration, and research coordination services. This is non-commercial in nature and supports operational costs including the C17 office staff.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

C17 Council is a non-profit national coordinating body for pediatric hematology, oncology, and stem cell transplant programs across Canada. It coordinates multi-centre research, administers a peer-reviewed annual research grant competition, runs the CYP-C national cancer surveillance program in collaboration with PHAC and CPAC, and expands access to early-phase clinical trials through the U-Link.care portal and DVL network.

Product overview

C17 Council is a national organization representing the 16 academic pediatric oncology/hematology programs across 17 centres in Canada. The organization operates through a unified platform consisting of the C17 Council itself, the C17 Research Network (which runs an annual peer-reviewed grant competition funding over $6.5M since 2005), the CYP-C national cancer surveillance program, the U-Link.care clinical trial finder portal, the 100% Fund for hard-to-treat pediatric cancers, the Developmental Therapeutics (DVL) Committee expanding Phase I/II trial access across 11 centres, the Education Committee developing training and guidelines, and the Adolescents and Young Adults (AYA) with Cancer Program addressing unique care needs for this population. These products work together to coordinate national pediatric hematology/oncology research, clinical care, education, and advocacy.

Differentiator

Problem solved

Functional benefit

Products and services

• CYP-C (Cancer in Young People in Canada) Surveillance Program
• U-Link.care Early-Phase Clinical Trial Portal
• C17 Research Grant Competition
• The 100% Fund
• DVL (Developmental Therapeutics) Committee Early-Phase Trial Network

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• Public Health Agency of Canada (PHAC)coreStrategic or Co-development PartnerCo-leads the Cancer in Young People in Canada (CYP-C) national surveillance program with C17 and CPAC. PHAC provides government mandate, regulatory oversight, and data governance for the collection of pediatric cancer diagnosis, treatment, and outcome data across Canadian centres.
• Canadian Partnership Against Cancer (CPAC)coreStrategic or Co-development PartnerCo-leads the CYP-C/CCJC surveillance program and jointly manages the Adolescents & Young Adults with Cancer program with C17. CPAC is the national cancer control agency that funds and coordinates cancer policy and surveillance initiatives in Canada.
• Children's Oncology Group (COG)coreStrategic or Co-development PartnerC17 holds the official Canadian Senior Medical Officer appointment for COG, the unified North American pediatric oncology research group (formed 2000 from CCG, POG, IRSG, NWTSG). C17's Senior Medical Office submits Health Canada regulatory documents and ensures sites comply with Health Canada Food and Drug Regulations for COG clinical trials conducted in Canada.
• Canadian Cancer Trials Group (CCTG)majorStrategic or Co-development PartnerC17's Developmental Therapeutics Committee partners with CCTG to open and conduct early-phase (Phase I/II) clinical studies in pediatric oncology. The first joint C17/CCTG study opened in September 2010.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• National Pediatric Cancer Foundation:
• CureSearch for Children's Cancer: CureSearch is a US-based foundation that funds pediatric cancer research and accelerates the development of new treatments. It plays a comparable role to C17's Research Network as a funder and convener of pediatric oncology research across multiple institutions, though at a larger US-based scale.
• Alex's Lemonade Stand Foundation for Childhood Cancer: Alex's Lemonade Stand Foundation is a large US childhood cancer research charity that funds grants, runs a childhood cancer registry, and supports research infrastructure. It plays a comparable funder/coordinator role to C17's Research Network and 100% Fund at a larger US scale.
• International Society of Paediatric Oncology (SIOP): SIOP is the global multidisciplinary society for pediatric oncology, hosting the world's leading congress and setting international research and treatment standards. It is a broader incumbent relative to C17's national coordination role, with overlapping member institutions and shared goals of advancing pediatric cancer outcomes.

Direct peers

• Children's Oncology Group (COG): COG is the largest pediatric oncology research cooperative group in North America and C17's primary international counterpart. C17 actually holds COG's Canadian Senior Medical Office appointment, making the two organizations deeply interlinked but operationally distinct coordinating bodies for pediatric cancer research.
• Therapeutic Advances in Childhood Leukemia (TACL): TACL is a multi-institutional consortium dedicated to early-phase clinical trials for childhood leukemia and lymphoma. It shares C17's focus on accelerating access to investigational therapies for pediatric hematologic malignancies through coordinated multi-site trials.
• Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC): POETIC is a US-based consortium focused on early-phase (Phase I) pediatric oncology clinical trials across multiple academic centers. Its mission closely parallels C17's Developmental Therapeutics Committee, which coordinates Phase I/II trials across 11 Canadian centres.
• Canadian Cancer Trials Group (CCTG): CCTG is Canada's national adult and pediatric cancer clinical trials cooperative group based at Queen's University. C17's Developmental Therapeutics Committee partners with CCTG to open and conduct Phase I/II pediatric oncology studies, and the two organizations perform overlapping clinical trial coordination roles in Canada.

Regional players

• Pediatric Oncology Group of Ontario (POGO): POGO coordinates pediatric oncology care, research, and surveillance across Ontario specifically. It is referenced in C17's CYP-C data access process and serves a comparable mission within a narrower provincial geography, making it a regional peer to C17's national scope.
• Nordic Society of Paediatric Haematology and Oncology (NOPHO): NOPHO coordinates pediatric hematology and oncology research and clinical care across the Nordic countries. It is the most direct international analog to C17: a regionally-scoped national council of pediatric oncology program heads performing clinical trials coordination, guideline development, and surveillance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/c17council
• LinkedInlinkedin.com/company/c17council
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C17 Council